Intracapsular Injection of Human Umbilical Cord Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis (KOA UC-MSCs)
Evaluating the Efficacy of Intra-articular Injection of Human Umbilical Cord Mesenchymal Stem Cells for Treating Knee Osteoarthritis
This is a self-controlled study comparing both knees. A total of 20 participants are planned to be enrolled. Among the first 10 participants, the same patient received 50 million mesenchymal stem cells and 2 ml of hyaluronic acid solution mixture in one knee as the experimental group, while the other knee was treated with 2 ml of hyaluronic acid injection solution as the control group. The first 10 patients did not experience any serious adverse events. After re-enrollment of the next 10 patients, the same patient was given 100 million mesenchymal stem cells and 2 ml of hyaluronic acid sodium mixture to one knee, while the other knee was given 2 ml of hyaluronic acid sodium injection as the experimental group. Compare the therapeutic effects between the two knees and among different doses.
Przegląd badań
Status
Interwencja / Leczenie
Typ studiów
Zapisy (Szacowany)
Faza
- Wczesna faza 1
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Patients with primary knee osteoarthritis aged between 45 and 75 years old;
- The X-ray of the bilateral knee joints shows a KL grade of 2-3 for both knees, and the grades of the bilateral knee joints are consistent;
- The difference in knee pain VAS score between both knees is no more than 2 points;
Exclusion Criteria:
- Those who have received joint cavity injection treatment within 3 months;
- Those who have experienced knee joint infection within 12 weeks, or knee joint injury within 12 weeks;
- Rheumatoid arthritis and other autoimmune joint diseases;
- Those with digestive tract ulcers, coronary heart disease and other conditions where the use of non-steroidal anti-inflammatory drugs is contraindicated;
- Those with tumors, diabetes, blood system diseases, local skin diseases and systemic allergies;
- Those with immunodeficiency or who have received immunosuppressive treatment within 12 weeks;
- Those with other serious diseases that cannot cooperate with the study.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nielosowe
- Model interwencyjny: Zadanie sekwencyjne
- Maskowanie: Potroić
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: treatment group
First, 10 subjects were enrolled. For one knee joint of each subject, a mixture of 5 million HUCMSCs and 2 ml of sodium hyaluronate was administered as the experimental group. If no serious adverse reactions occurred among the first 10 patients, the remaining 10 subjects were enrolled, and the other knee joint of each subject was treated with 100 million HUCMSCs and 2 ml of sodium hyaluronate as the experimental group. |
Procedure for knee joint injection: The patient lies on their back, with the knee joint flexed at 90 degrees. The knee joint is disinfected with iodine and alcohol, and a sterile sheet is laid out. The puncture point for the knee joint is selected at the inner or outer knee crease or the supra-patellar bursa approach. Using a joint cavity puncture needle (a 19-gauge needle), insert the needle vertically through the skin at the puncture point. There is a slight sense of firmness when passing through the joint capsule, and a feeling of emptiness when it is broken through. There is no resistance when injecting the fluid, and the drug can be injected. |
|
Komparator placebo: control group
The control group was given 2 ml of sodium hyaluronate.The control group was given 2 ml of sodium hyaluronate. |
Procedure for knee joint injection: The patient lies on their back, with the knee joint flexed at 90 degrees. The knee joint is disinfected with iodine and alcohol, and a sterile sheet is laid out. The puncture point for the knee joint is selected at the inner or outer knee crease or the supra-patellar bursa approach. Using a joint cavity puncture needle (a 19-gauge needle), insert the needle vertically through the skin at the puncture point. There is a slight sense of firmness when passing through the joint capsule, and a feeling of emptiness when it is broken through. There is no resistance when injecting the fluid, and the drug can be injected. |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Adverse reaction grade
Ramy czasowe: From the beginning of the treatment to 28 days after the treatment.
|
Blood pressure was recorded during the transplantation process and on the 3rd, 7th, 14th and 28th days after the transplantation. |
From the beginning of the treatment to 28 days after the treatment.
|
|
Adverse reaction grade
Ramy czasowe: From the beginning of the treatment to 28 days after the treatment.
|
During the transplantation process and on the 3rd, 7th, 14th and 28th days after transplantation, record the heart rate. |
From the beginning of the treatment to 28 days after the treatment.
|
|
Adverse reaction grade
Ramy czasowe: From the beginning of the treatment to 28 days after the treatment.
|
During the transplantation process and on the 3rd, 7th, 14th and 28th days after transplantation, record the body temperature. |
From the beginning of the treatment to 28 days after the treatment.
|
|
Adverse reaction grade
Ramy czasowe: From the beginning of the treatment to 28 days after the treatment.
|
During the transplantation process and on the 3rd, 7th, 14th and 28th days after transplantation, observe whether any rash occurs. |
From the beginning of the treatment to 28 days after the treatment.
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Clinical effectiveness
Ramy czasowe: From the beginning of the treatment to two years after the treatment
|
patient pain score (VAS score)： 0 point: Completely pain-free, no discomfort. 1-3 points (mild): There is pain, but it does not affect sleep or daily activities and can be tolerated; 4-6 points (moderate): Severe pain that significantly affects sleep, requiring distraction to cope with it, and usually requiring medication intervention; 7-10 points (severe): Significantly interferes with daily life, unbearable, may result in inability to move or sleep, requires strong pain relief. |
From the beginning of the treatment to two years after the treatment
|
|
Clinical effectiveness
Ramy czasowe: From the beginning of the treatment to two years after the treatment
|
joint function score (KSS score) Including clinical scores and functional scores. |
From the beginning of the treatment to two years after the treatment
|
|
Clinical effectiveness
Ramy czasowe: From the beginning of the treatment to two years after the treatment
|
quality of life score (SF-12) |
From the beginning of the treatment to two years after the treatment
|
|
Clinical effectiveness
Ramy czasowe: From the beginning of the treatment to two years after the treatment
|
WORMS score |
From the beginning of the treatment to two years after the treatment
|
Współpracownicy i badacze
Sponsor
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- 2026BJYYEC-XJS001
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Typ informacji pomocniczych dotyczących udostępniania IPD
- CSR
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .